Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
62 Leser
Artikel bewerten:
(0)

Biotest Pharmaceuticals Corporation Announces the Opening of its Newest Plasma Collection Facility in Valdosta, Georgia

BOCA RATON, Fla., July 2, 2014 /PRNewswire/ --Biotest Pharmaceuticals Corporation (BPC), a leading developer of immunology biotherapeutic products, is pleased to announce the addition of its newest plasma collection center located at 311 North Patterson Road, in Valdosta, Georgia. The almost 16,000 square foot state-of-the-art facility officially opened its doors for business on June 30th 2014 and brings the total number of BPC's plasma collection centers to sixteen.

"This Center is the second facility we've opened in 2014, reinforcing our continued commitment in the expansion of our existing network of centers to better serve the thousands of patients that rely on plasma based therapies," said Jordan Siegel, BPC's Chief Executive Officer.

The plasma donated at Biotest Plasma Centers is used to manufacture critical care therapies that treat life threatening disorders in a variety of therapeutic areas, such as BPC's BIVIGAM® [Immune Globulin Intravenous (Human), 10% Liquid] and Nabi-HB® [Hepatitis B Immune Globulin (Human)].

BPC has invested approximately $2.0 million in construction of this facility. The Company expects to add over fifty jobs to Valdosta's local economy and currently has employment opportunities available for medical personnel and phlebotomists.

In addition to supporting the local economy through employment opportunities, the plasma center is actively recruiting local residents to donate plasma. Plasma donors not only contribute the source material for these plasma derived therapies that save the lives of thousands of patients but also are compensated for their donations.

About Biotest Pharmaceuticals Corporation

Biotest Pharmaceuticals Corporation develops and manufactures pharmaceutical and biotherapeutic products with a specialization in immunology. Biotest Pharmaceuticals was formed in 2007 as part of the Biotest AG acquisition of Nabi Pharmaceuticals' Biologics business unit, including its plasmapheresis centers across the United States. The company employs over 600 people in the U.S. Biotest Pharmaceuticals is a subsidiary of Biotest AG, a German-based global provider of plasma proteins that employs approximately 2,000 people worldwide. To learn more about Biotest Pharmaceuticals and how we help make a difference in the lives of patients and the healthcare community, please visit us at www.biotestpharma.com.

SOURCE Biotest Pharmaceuticals Corporation

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.